204,406 Pfizer Inc. $PFE Shares Bought by United Asset Strategies Inc.

Key Points

• United Asset Strategies increased its Pfizer stake by 762.9% in the third quarter, buying 204,406 additional shares for a total holding of 231,199 shares valued at approximately $6.6 million.
• Analysts maintain a broadly cautious outlook, with Pfizer receiving a consensus “Hold” rating and an average price target of $28.72, despite some firms issuing Buy or Outperform ratings.
• Pfizer shares opened at $29.91, while the company reported quarterly earnings and revenue above expectations and declared a quarterly dividend of $0.43, representing an annualized yield of about 5.8%.

United Asset Strategies Inc. increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 762.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 231,199 shares of the biopharmaceutical company's stock after acquiring an additional 204,406 shares during the period. United Asset Strategies Inc.'s holdings in Pfizer were worth $6,594,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC raised its position in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 509 shares in the last quarter. Evolution Wealth Management Inc. boosted its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Keb Asset Management LLC purchased a new position in shares of Pfizer in the 2nd quarter worth about $26,000. Field & Main Bank bought a new position in shares of Pfizer during the 2nd quarter valued at about $27,000. Finally, Global Trust Asset Management LLC increased its position in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 650 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PFE shares. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 9th. Weiss Ratings raised shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, October 13th. Finally, Scotiabank boosted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of "Hold" and an average target price of $28.72.

Pfizer Stock Up 1.6%

Shares of NYSE:PFE opened at $29.91 on Friday. The stock has a market capitalization of $170.49 billion, a P/E ratio of 9.66, a price-to-earnings-growth ratio of 2.00 and a beta of 0.32. The stock's 50-day moving average price is $28.49 and its 200-day moving average price is $26.76. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $30.44.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's payout ratio is 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that ELREXFIO met the primary endpoint in a second Phase 3 multiple myeloma trial. The result strengthens the drug’s position as a potential growth product that could help offset declines in pandemic-related revenue. Pfizer’s Elrexfio meets primary endpoint in second Phase III myeloma trial
• Positive Sentiment: Pfizer entered an agreement with Edison Scientific to accelerate research and development. While financial terms and specific programs were not disclosed, the collaboration could improve drug-discovery productivity and support the company’s longer-term pipeline. Edison Scientific Announces Agreement with Pfizer
• Positive Sentiment: A new industry report projects the global HER2-targeted therapies market will grow at roughly 8% annually through 2026. Pfizer is listed among companies advancing antibody-drug conjugates and precision-oncology treatments, providing a favorable backdrop for its oncology strategy. Global HER2 Targeted Therapies Market Report 2026
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter results, scheduled for November 3. Analysts are assessing whether non-COVID products, cost controls and progress in obesity treatments can counter continued erosion in COVID-product sales. Obesity Pipeline vs. COVID Drag
• Negative Sentiment: ELREXFIO’s trial success came with higher infection rates, creating a safety consideration that could affect adoption, labeling or investor expectations despite the efficacy milestone. Pfizer’s ELREXFIO Meets Phase 3 Endpoint

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.